Shares of Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) dropped 1.4% during mid-day trading on Monday . The company traded as low as $2.05 and last traded at $2.07. Approximately 43,921 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 166,032 shares. The stock had previously closed at $2.10.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Entera Bio in a research report on Monday, November 11th.
Check Out Our Latest Stock Analysis on ENTX
Entera Bio Stock Down 8.4 %
The business's 50-day simple moving average is $2.31 and its 200-day simple moving average is $1.99. The stock has a market cap of $66.20 million, a PE ratio of -7.12 and a beta of 1.52.
Hedge Funds Weigh In On Entera Bio
A number of hedge funds have recently modified their holdings of ENTX. Knoll Capital Management LLC increased its position in shares of Entera Bio by 51.5% during the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after buying an additional 2,000,000 shares during the period. Northern Trust Corp purchased a new position in shares of Entera Bio during the fourth quarter valued at about $450,000. Perigon Wealth Management LLC purchased a new position in shares of Entera Bio during the fourth quarter valued at about $325,000. Signature Estate & Investment Advisors LLC purchased a new position in shares of Entera Bio during the third quarter valued at about $90,000. Finally, Parkman Healthcare Partners LLC increased its position in shares of Entera Bio by 2.4% during the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company's stock valued at $781,000 after buying an additional 9,558 shares during the period. Hedge funds and other institutional investors own 14.11% of the company's stock.
About Entera Bio
(
Get Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
See Also
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
